Felicitas R. Thol

Internal Medicine

1 Medical Center Dr
Lebanon, NH 03756

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 182 publications

DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy.

DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy.

Journal: BMC cancer

Published: June 16, 2026

Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia.

Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 27, 2026

Rapid and Reproducible Karyotyping with Long Read Sequencing in AML Patients.

Rapid and Reproducible Karyotyping with Long Read Sequencing in AML Patients.

Journal: Blood advances

Published: February 02, 2026

Postoperative Pain Management in Orthognathic Surgery: Is There a Need for Opioids?

Postoperative Pain Management in Orthognathic Surgery: Is There a Need for Opioids?

Journal: The Journal of craniofacial surgery

Published: January 27, 2026

Eltrombopag plus cyclosporine A for moderate aplastic anemia (EMAA): a placebo-controlled, double-blind, phase 3 trial.

Eltrombopag plus cyclosporine A for moderate aplastic anemia (EMAA): a placebo-controlled, double-blind, phase 3 trial.

Journal: Blood

Published: January 23, 2026

Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia.

Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia.

Journal: Leukemia

Published: October 20, 2025

2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party.

2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party.

Journal: Blood

Published: September 16, 2025

2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party.

2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party.

Journal: Blood

Published: September 16, 2025

Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.

Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.

Journal: Leukemia

Published: August 15, 2025

Prognostic Role of Kidney Disease in Newly Diagnosed Acute Myeloid Leukemia Under Venetoclax-Based Low-Intensity Therapy.

Prognostic Role of Kidney Disease in Newly Diagnosed Acute Myeloid Leukemia Under Venetoclax-Based Low-Intensity Therapy.

Journal: Cancers

Published: August 14, 2025

CPX-351 in Down syndrome-associated myeloid leukemia: results and prognostic factors from the phase 3 ML-DS 2018 trial.

CPX-351 in Down syndrome-associated myeloid leukemia: results and prognostic factors from the phase 3 ML-DS 2018 trial.

Journal: Blood

Published: July 14, 2025

A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

Journal: Blood

Published: July 09, 2025

Showing 1-12 of 182

Last Updated: 09/26/2026